Display options
Cite
Abarrategi A, Tornin J, Martinez-Cruzado L, et al. Osteosarcoma: Cells-of-Origin, Cancer Stem Cells, and Targeted Therapies. Stem Cells Int. 2016;2016:3631764doi: 10.1155/2016/3631764.
Abarrategi, A., Tornin, J., Martinez-Cruzado, L., Hamilton, A., Martinez-Campos, E., Rodrigo, J. P., González, M. V., Baldini, N., Garcia-Castro, J., & Rodriguez, R. (2016). Osteosarcoma: Cells-of-Origin, Cancer Stem Cells, and Targeted Therapies. Stem cells international, 20163631764. https://doi.org/10.1155/2016/3631764
Abarrategi, Ander, et al. "Osteosarcoma: Cells-of-Origin, Cancer Stem Cells, and Targeted Therapies." Stem cells international vol. 2016 (2016): 3631764. doi: https://doi.org/10.1155/2016/3631764
Abarrategi A, Tornin J, Martinez-Cruzado L, Hamilton A, Martinez-Campos E, Rodrigo JP, González MV, Baldini N, Garcia-Castro J, Rodriguez R. Osteosarcoma: Cells-of-Origin, Cancer Stem Cells, and Targeted Therapies. Stem Cells Int. 2016;2016:3631764. doi: 10.1155/2016/3631764. Epub 2016 Jun 05. PMID: 27366153; PMCID: PMC4913005.
Copy Download .nbib Format: NLM
Share it on

Stem Cells Int. 2016;2016:3631764. doi: 10.1155/2016/3631764. Epub 2016 Jun 05.

Osteosarcoma: Cells-of-Origin, Cancer Stem Cells, and Targeted Therapies.

Stem cells international

Ander Abarrategi, Juan Tornin, Lucia Martinez-Cruzado, Ashley Hamilton, Enrique Martinez-Campos, Juan P Rodrigo, M Victoria González, Nicola Baldini, Javier Garcia-Castro, Rene Rodriguez

Affiliations

  1. Haematopoietic Stem Cell Laboratory, The Francis Crick Institute, London WC2A 3LY, UK.
  2. Central University Hospital of Asturias (HUCA) and Institute of Oncology of Asturias (IUOPA), 33011 Oviedo, Spain.
  3. Complutense University of Madrid, 28040 Madrid, Spain.
  4. Orthopaedic Pathophysiology and Regenerative Medicine Unit, Rizzoli Orthopaedic Institute, 40136 Bologna, Italy; Department of Biomedical and Neuromotor Sciences, University of Bologna, 40123 Bologna, Italy.
  5. Cellular Biotechnology Laboratory, Institute of Health Carlos III (ISCIII), Majadahonda, 28220 Madrid, Spain.

PMID: 27366153 PMCID: PMC4913005 DOI: 10.1155/2016/3631764

Abstract

Osteosarcoma (OS) is the most common type of primary solid tumor that develops in bone. Although standard chemotherapy has significantly improved long-term survival over the past few decades, the outcome for those patients with metastatic or recurrent OS remains dismally poor and, therefore, novel agents and treatment regimens are urgently required. A hypothesis to explain the resistance of OS to chemotherapy is the existence of drug resistant CSCs with progenitor properties that are responsible of tumor relapses and metastasis. These subpopulations of CSCs commonly emerge during tumor evolution from the cell-of-origin, which are the normal cells that acquire the first cancer-promoting mutations to initiate tumor formation. In OS, several cell types along the osteogenic lineage have been proposed as cell-of-origin. Both the cell-of-origin and their derived CSC subpopulations are highly influenced by environmental and epigenetic factors and, therefore, targeting the OS-CSC environment and niche is the rationale for many recently postulated therapies. Likewise, some strategies for targeting CSC-associated signaling pathways have already been tested in both preclinical and clinical settings. This review recapitulates current OS cell-of-origin models, the properties of the OS-CSC and its niche, and potential new therapies able to target OS-CSCs.

References

  1. Cell Res. 2012 Jan;22(1):62-77 - PubMed
  2. Oncogene. 2015 Aug 6;34(32):4278-84 - PubMed
  3. J Orthop Surg Res. 2010 Oct 27;5:78 - PubMed
  4. FASEB J. 2013 Jan;27(1):13-24 - PubMed
  5. J Pathol. 2009 Nov;219(3):294-305 - PubMed
  6. J Natl Cancer Inst. 2003 May 7;95(9):669-74 - PubMed
  7. Int J Oncol. 2014 Nov;45(5):2013-23 - PubMed
  8. Nat Rev Cancer. 2014 Nov;14(11):722-35 - PubMed
  9. Mol Med Rep. 2015 Apr;11(4):2534-40 - PubMed
  10. Sarcoma. 2012;2012:704872 - PubMed
  11. Int J Biol Sci. 2012;8(2):272-88 - PubMed
  12. Oncogene. 2013 Oct 10;32(41):4970-80 - PubMed
  13. J Cell Biochem. 2014 Apr;115(4):625-31 - PubMed
  14. Nature. 2010 Aug 26;466(7310):1110-4 - PubMed
  15. Cancer Res. 1993 Jan 1;53(1):16-8 - PubMed
  16. Stem Cells. 2013 Mar;31(3):433-46 - PubMed
  17. Clin Cancer Res. 2010 Aug 15;16(16):4256-67 - PubMed
  18. Sarcoma. 1997;1(3-4):131-4 - PubMed
  19. Bone. 2003 Apr;32(4):364-71 - PubMed
  20. Tumour Biol. 2014 Feb;35(2):1075-82 - PubMed
  21. Stem Cells. 2013 Oct;31(10):2061-72 - PubMed
  22. J Med Chem. 2015 May 14;58(9):4073-9 - PubMed
  23. Cancer Res. 1994 Jun 1;54(11):3042-8 - PubMed
  24. FEBS J. 2012 Jun;279(12):2247-59 - PubMed
  25. Oncotarget. 2016 May 24;7(21):30935-50 - PubMed
  26. Int J Oncol. 2013 Jul;43(1):95-102 - PubMed
  27. Cell Mol Life Sci. 2015 Aug;72(16):3097-113 - PubMed
  28. N Engl J Med. 1992 May 14;326(20):1309-15 - PubMed
  29. Sarcoma. 2012;2012:359739 - PubMed
  30. Curr Opin Pharmacol. 2014 Jun;16:15-23 - PubMed
  31. Proc Natl Acad Sci U S A. 2008 Aug 19;105(33):11851-6 - PubMed
  32. Bone. 2015 Nov;80:19-23 - PubMed
  33. Chin J Cancer. 2011 Jun;30(6):426-32 - PubMed
  34. J Cell Biochem. 2015 Aug;116(8):1719-29 - PubMed
  35. Oncogene. 2010 Oct 21;29(42):5687-99 - PubMed
  36. Clin Orthop Relat Res. 2012 Aug;470(8):2288-94 - PubMed
  37. Tumour Biol. 2015 Dec;36(12 ):9873-83 - PubMed
  38. J Clin Invest. 2010 Sep;120(9):3310-25 - PubMed
  39. Front Oncol. 2013 Jun 27;3:168 - PubMed
  40. Vet J. 2008 Jan;175(1):69-75 - PubMed
  41. Acta Oncol. 2011 Nov;50(8):1142-50 - PubMed
  42. Int J Cancer. 2015 Feb 15;136(4):784-96 - PubMed
  43. J Cell Physiol. 2013 Jun;228(6):1189-201 - PubMed
  44. Cancer Biol Ther. 2009 Mar 15;8(6):543-52 - PubMed
  45. Neoplasia. 2005 Nov;7(11):967-76 - PubMed
  46. Ann Oncol. 2008 Aug;19(8):1500-8 - PubMed
  47. Oncol Lett. 2014 Jan;7(1):239-244 - PubMed
  48. PLoS One. 2014 Oct 20;9(10):e110340 - PubMed
  49. Mol Cancer. 2010 Apr 30;9:96 - PubMed
  50. PLoS One. 2014 Jun 03;9(6):e98549 - PubMed
  51. J Cell Physiol. 2009 May;219(2):301-13 - PubMed
  52. Oncol Rep. 2010 Aug;24(2):501-5 - PubMed
  53. Clin Sarcoma Res. 2013 Jul 23;3(1):10 - PubMed
  54. Cancer Res. 2007 Aug 1;67(15):7308-18 - PubMed
  55. Cancer Cell. 2014 Sep 8;26(3):390-401 - PubMed
  56. Int J Nanomedicine. 2015 Mar 31;10 :2537-54 - PubMed
  57. J Mol Diagn. 2011 May;13(3):289-96 - PubMed
  58. Mol Med Rep. 2015 Oct;12 (4):5042-8 - PubMed
  59. Clin Cancer Res. 2014 Oct 1;20(19):5097-112 - PubMed
  60. Nat Commun. 2015 Dec 03;6:8940 - PubMed
  61. Biomed Res Int. 2015;2015:290368 - PubMed
  62. Sarcoma. 2011;2011:959248 - PubMed
  63. Cancer Lett. 2011 Dec 1;311(1):113-21 - PubMed
  64. Stem Cells. 2010 Jul;28(7):1119-31 - PubMed
  65. Expert Opin Emerg Drugs. 2015 Sep;20(3):495-514 - PubMed
  66. Oncogene. 2009 Nov 19;28(46):4065-74 - PubMed
  67. Oncotarget. 2013 Dec;4(12):2326-38 - PubMed
  68. BMC Cancer. 2012 Apr 04;12:139 - PubMed
  69. Oncology. 1998 Nov-Dec;55(6):556-63 - PubMed
  70. Genes Dev. 2008 Jun 15;22(12):1662-76 - PubMed
  71. Cancer Metastasis Rev. 2006 Dec;25(4):707-13 - PubMed
  72. Br J Cancer. 1995 Aug;72(2):393-8 - PubMed
  73. Cell Death Dis. 2014 Feb 27;5:e1093 - PubMed
  74. Oncotarget. 2015 Sep 15;6(27):23662-70 - PubMed
  75. J Cell Biochem. 2012 Apr;113(4):1282-91 - PubMed
  76. Cell Physiol Biochem. 2015;36(3):1186-96 - PubMed
  77. Oncotarget. 2015 Jun 10;6(16):14413-27 - PubMed
  78. Bone. 2013 Jul;55(1):166-78 - PubMed
  79. Cancer Res. 2010 May 15;70(10):4185-94 - PubMed
  80. Adv Exp Med Biol. 2014;804:341-53 - PubMed
  81. Stem Cells. 2014 May;32(5):1136-48 - PubMed
  82. Proteomics. 2013 Nov;13(22):3293-7 - PubMed
  83. Cell Stem Cell. 2015 Mar 5;16(3):225-38 - PubMed
  84. Oncol Lett. 2014 May;7(5):1352-1362 - PubMed
  85. Mol Med Rep. 2009 Mar-Apr;2(2):245-52 - PubMed
  86. Bonekey Rep. 2013 Jul 17;2:378 - PubMed
  87. Mol Med Rep. 2013 Feb;7(2):577-84 - PubMed
  88. Nature. 2011 Jan 20;469(7330):314-22 - PubMed
  89. Cancer Res. 2010 Jun 1;70(11):4602-12 - PubMed
  90. Br J Cancer. 2009 Dec 1;101(11):1909-18 - PubMed
  91. Cancer Lett. 2016 Jan 28;370(2):268-74 - PubMed
  92. Oncology. 2015;88(4):257-60 - PubMed
  93. Arch Biochem Biophys. 2008 May 15;473(2):139-46 - PubMed
  94. Oncogene. 1990 Jul;5(7):989-1000 - PubMed
  95. Oncogene. 2014 Oct 2;33(40):4857-66 - PubMed
  96. Front Oncol. 2013 May 31;3:132 - PubMed
  97. JAMA. 1997 Oct 15;278(15):1262-7 - PubMed
  98. J Cell Physiol. 2010 Feb;222(2):268-77 - PubMed
  99. Dis Model Mech. 2012 Nov;5(6):756-62 - PubMed
  100. Adv Exp Med Biol. 2012;741:187-205 - PubMed
  101. Stem Cells. 2014 Apr;32(4):959-73 - PubMed
  102. Lancet Oncol. 2012 Feb;13(2):e83-9 - PubMed
  103. Oncogene. 2012 May 3;31(18):2270-82 - PubMed
  104. Sarcoma. 2011;2011:679457 - PubMed
  105. Cancer Genet Cytogenet. 2005 Apr 15;158(2):142-7 - PubMed
  106. Sarcoma. 2011;2011:694136 - PubMed
  107. Diagn Mol Pathol. 2004 Jun;13(2):81-91 - PubMed
  108. Expert Rev Anticancer Ther. 2011 Aug;11(8):1223-32 - PubMed
  109. Life Sci. 2015 Jun 1;130:47-56 - PubMed
  110. Int J Oncol. 2009 May;34(5):1381-6 - PubMed
  111. Front Oncol. 2013 Jun 11;3:143 - PubMed
  112. Carcinogenesis. 2013 Jul;34(7):1601-10 - PubMed
  113. Clin Orthop Relat Res. 2008 Sep;466(9):2114-30 - PubMed
  114. Nat Genet. 2015 Jun;47(6):615-24 - PubMed
  115. Cancer Lett. 2013 Sep 10;338(1):158-67 - PubMed
  116. Cancer. 1997 Apr 15;79(8):1541-7 - PubMed
  117. Mol Med Rep. 2015 Oct;12 (4):5665-70 - PubMed
  118. Cancer Gene Ther. 2012 Mar;19(3):212-7 - PubMed
  119. Biochem Biophys Res Commun. 2013 Feb 8;431(2):274-9 - PubMed
  120. Adv Exp Med Biol. 2014;804:323-40 - PubMed
  121. Genes Chromosomes Cancer. 2012 Jul;51(7):696-706 - PubMed
  122. Curr Pharm Des. 2010;16(27):2981-7 - PubMed
  123. Neoplasia. 2007 Aug;9(8):678-88 - PubMed
  124. Proc Natl Acad Sci U S A. 2003 Sep 30;100(20):11547-52 - PubMed
  125. Mol Cancer Ther. 2008 Oct;7(10):3389-98 - PubMed
  126. Int J Oncol. 2015;46(6):2573-85 - PubMed
  127. J Cell Physiol. 2016 Apr;231(4):876-86 - PubMed
  128. Asian Pac J Cancer Prev. 2012;13(7):3103-7 - PubMed
  129. Carcinogenesis. 2009 Oct;30(10):1789-95 - PubMed
  130. Orthop Clin North Am. 2015 Oct;46(4):587-608 - PubMed
  131. Oncol Rep. 2014 Jan;31(1):370-5 - PubMed
  132. Cell. 1998 Mar 20;92 (6):725-34 - PubMed
  133. FASEB J. 2011 Jun;25(6):2022-30 - PubMed
  134. Br J Cancer. 2009 Oct 20;101(8):1425-32 - PubMed
  135. Cancer Lett. 2011 Dec 27;313(2):129-36 - PubMed
  136. Cell Rep. 2014 Apr 10;7(1):104-12 - PubMed
  137. Mol Ther. 2015 Jan;23(1):89-98 - PubMed
  138. J Cell Biochem. 2014 Aug;115(8):1420-9 - PubMed
  139. Cancer Gene Ther. 2015 Nov;22(11):524-9 - PubMed
  140. Int J Cancer. 1999 Oct 22;84(5):489-93 - PubMed
  141. Clin Sarcoma Res. 2012 Oct 04;2(1):19 - PubMed
  142. Cancer Sci. 2011 Oct;102(10 ):1774-81 - PubMed
  143. Cancer Res. 2009 Jul 15;69(14 ):5648-55 - PubMed
  144. Int J Cancer. 2011 Jan 15;128(2):294-303 - PubMed
  145. Cancer Res. 2009 Mar 15;69(6):2559-67 - PubMed
  146. Bone. 2014 May;62:56-63 - PubMed
  147. Cancer Res. 1995 Dec 15;55(24):6244-51 - PubMed

Publication Types